In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in ...
Data from an early trial showed the company’s “gamma delta” cell therapy surpassed benchmarks set by personalized CAR-T ...
Mivocabtagene autoleucel (miv-cel), an autologous CD19 chimeric antigen receptor (CAR)-T cell therapy, showed benefits ...
In this segment, Dr. Peter Voorhees and Dr. Doris Hansen discuss the safety profile and post-treatment management of CAR ...
The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, ...
Subsequent decreasing rates of OS and PFS point to the challenge of long-term CAR T-Cell efficacy and durability of treatment.
A review from researchers at Naval Medical University and Shanghai Jiao Tong University examines how engineering CAR T cells ...
CAR-T cell therapies developed in China are quickly moving to trials in patients. Credit: Qilai Shen/Bloomberg via Getty.
Adami first learned about CAR T in 2012 at a screening of Fire With Fire, the film about Emily Whitehead, the first pediatric ...
Predictions for the 2026 Nobel Prizes in science highlight significant contributions in areas like GLP-1 research and cancer therapies. Carl June is mentioned for his role in developing CAR-T cell ...
People don’t realize, too, that CAR T, even when it’s done, you still need disease monitoring. There’s B-cell defects ...
Treatment options for patients with relapsed/refractory follicular lymphoma have expanded rapidly. CD19-directed CAR T-cell therapies are approved in the third-line setting and beyond, and CD20 x CD3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results